Status:
COMPLETED
Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema
Lead Sponsor:
Saglik Bilimleri Universitesi
Conditions:
Diabetic Macular Edema
Inflammation
Eligibility:
All Genders
18-90 years
Brief Summary
The current study aims to investigate the relationship between systemic inflammatory biomarkers and local inflammatory biomarkers on OCT in patients with treatment resistant diabetic macular edema(DME...
Detailed Description
This study was designed as a prospective open-label non rondomised observational study. The study was registered between April 18, 2022 and October 18, 2023. It is planned to include 80 volunteer pati...
Eligibility Criteria
Inclusion
- who had refractory DME after 3 consecutive initial bevacizumab therapy
- treatment-naive
Exclusion
- who had underwent anti-vegf treatment previously
- systemic inflammatory disease
- who had ocular surgery 6 months prior to enrollment
- uncontrolled hypertension
- \<18 years old
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06179030
Start Date
May 1 2022
End Date
October 17 2023
Last Update
January 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, Sisli, Turkey (Türkiye), 34384